Business Wire

Vantage Data Centers to Continue Deploying Renewable Generator Fuel, Plans Rollout in Additional Markets in 2023

Share

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced the continued deployment of hydrotreated vegetable oil (HVO), a renewable fuel to replace conventional diesel fuel in generators. The company will roll out HVO in several of its largest markets in North America and EMEA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913529341/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vantage Data Centers continues rollout of HVO in several of its largest markets, including its Cardiff campus pictured here. (Photo: Business Wire)

HVO is 100% biodegradable and non-toxic, offering a more sustainable fuel option while delivering the same level of functionality as traditional diesel. Repurposing waste oils like vegetable oil to create sustainable fuels significantly reduces the embodied carbon due to the cleaner sourcing and creation process. Leveraging HVO offers an actionable opportunity for Vantage and other data center operators to take a positive step toward reducing carbon emissions.

Initially deployed as a pilot at Vantage’s Cardiff, Wales campus in 2022, the company’s deployment of HVO as an alternative to diesel fuel yielded progress toward its carbon goals without the need for new or updated infrastructure. Given the success of the pilot, Vantage officially implemented HVO at its newest facility, CWL13, on the Cardiff campus and is currently working to deploy the renewable fuel throughout the rest of the campus. In addition, Vantage will deploy HVO in one of its North American flagship markets, Santa Clara, California, by the end of the year. Vantage is planning deployments in additional markets subject to fuel availability.

“Making the switch to renewable diesel is one of the many ways we are reducing the carbon emissions of our operations. Reaching net zero by 2030 is an incredibly ambitious goal that will require us to implement a wide variety of solutions. Our focus is on maintaining reliability and affordability while achieving emissions reductions,” said Amanda Abell, senior director of sustainability at Vantage. “We look forward to continuing the rollout of HVO at our campuses across North America and EMEA, where available, in addition to the other programs we have in place to reach our sustainability targets.”

The broad launch of hydrotreated vegetable oil comes as the company progresses toward its sustainability goals. The use of renewable diesel fuels significantly reduces the embodied carbon of the fuel consumed in diesel generators, which helps to reduce Scope 3 emissions associated with the company’s supply chain. According to fuel suppliers, the use of HVO reduces the lifecycle carbon emissions by 65-90% compared to conventional diesel.

In 2022, Vantage partnered with the Data Center Coalition (DCC) and its members to lead a technical working group focused on driving market support for HVO as availability and costs vary by geography. Based in the Northern Virginia area, where HVO prices are approximately 95 percent higher than diesel fuel, DCC seeks to influence the supply chain and stakeholders to unlock increased availability.

“Vantage is working with industry through the Data Center Coalition to accelerate the viability and use of renewable diesel fuels,” said Mark Freeman, vice president, global marketing and public policy at Vantage and Data Center Coalition board member. “By collaborating and sharing information with peers, it helps the entire sector move faster. It is our hope that through partnerships we can convince policy makers, stakeholders and supply chains of the HVO benefits and enlist their help in achieving the widespread production and distribution of the renewable fuel in markets that lack reliable, cost-effective and timely access today.”

“There is strong industry interest in transitioning from diesel as quickly as is practical. While there are no ‘silver bullet’ technological solutions available today to replace backup diesel generators at scale, data centers are actively seeking and evaluating alternatives that can provide environmental sustainability benefits and similar reliability, fuel availability, siting flexibility and workplace safety protections,” explained Josh Levi, president of the Data Center Coalition. “We are seeing widespread interest in leveraging hydrotreated vegetable oil as an alternative to conventional diesel. In fact, a recent member survey found that 92 percent of respondents are interested in piloting renewable diesel in the Northern Virginia market within the next one to two years. We’re pleased to see support for this sustainable fuel and will continue to work closely with member companies as we advocate to speed the viability and availability of alternative, reliable sources for backup energy.”

In addition to Vantage’s continued rollout of HVO, the company is also implementing generator run-time reduction measures to eliminate the creation of emissions from the start. By using an optimized staged implementation of testing and maintenance procedures, Vantage anticipates achieving a 25 to 75 percent reduction in fuel consumption and associated emissions. Vantage is also installing active emissions control systems known as Selective Catalytic Reductions (SCRs) on generators in select markets. SCRs reduce nitrogen oxide emitted from the company’s diesel generators by up to 90%. SCRs are already installed at many facilities across Vantage’s Warsaw, Berlin, Frankfurt and California campuses with additional installations planned for the future.

For more information about Vantage’s sustainability program and priorities, download the 2022 ESG report here.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit http://www.vantage-dc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contacts
Mark Freeman
Vantage Data Centers
mfreeman@vantage-dc.com
+1-202-680-4243

Robin Bectel
REQ for Vantage Data Centers
vdc@req.co
+1-202-936-6335

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye